Cyclerion Therapeutics, Inc. (CYCN)
Oxford Ledge is still expanding full research coverage of CYCN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Cyclerion develops anesthetic-based therapies for treatment-resistant depression, with its lead program CYC-126 entering Phase 2 trials in 2026.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 10-K/A Amended annual report 2026-04-30
- 8-K Entry into material agreement; 5.01; Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-04-01
- 10-K Annual financial report with audited statements 2026-03-30
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-02-17
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CYCN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CYCN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.